Mitsubishi Heavy Industries Gets Japan Missile Contract
By Chieko Tsuneoka
TOKYO--Japan's Defense Ministry said Tuesday that it has awarded contracts worth 378 billion Japanese yen ($2.83 billion) to the country's top defense contractor, Mitsubishi Heavy Industries Ltd., to develop and mass-produce a series of new longer-range missiles.
The missiles, sometimes called standoff missiles, are capable of striking a distant target while lowering the risk of the enemy striking back. They have a longer range compared to Japan's existing missiles, which aren't intended to attack other countries' territory.
In December, Japan said it would raise defense spending over five years to 2% of gross domestic product, up from slightly more than 1% currently.
The four contracts were signed between April 3 and April 7, the Defense Ministry said. They call for development and production of land, sea and air-based cruise missiles with a range of 1,000 kilometers or more.
Under the contracts, Mitsubishi will also build a hypersonic glide vehicle that the ministry expects to start deploying in the fiscal year beginning April 2026, and it will develop a cruise missile to be launched from submarines.
In addition to the home-grown missiles made by Mitsubishi, Japan has earmarked JPY211 billion to purchase 400 Tomahawk cruise missiles from the U.S. They are scheduled to be operational some time after spring 2026.
Write to Chieko Tsuneoka at chieko.tsuneoka@wsj.com
(END) Dow Jones Newswires
April 11, 2023 09:09 ET (13:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth